Table 1.
Participant Demographic and Clinical Information
| AH (n=42) | VH (n=39) | NH (n=60) | HC (n=153) | |
|---|---|---|---|---|
| Demographic Info | ||||
| Age | 37.8 (11.9) | 37.1 (11.4) | 40.0 (11.8) | 37.8 (11.4) |
| Gender | 32 (m), 10 (f) | 30 (m), 9 (f) | 43 (m), 17 (f) | 108 (m), 45 (f) |
| Handedness (r/l/a) | 36 (r), 5 (l), 1 (a) | 32 (r), 5 (l), 2 (a) | 60 (r), 0 (l), 0 (a) | 83 144 (r), 7 (l), 2 (a) |
| Smoking Status | 19 (s), 23 (n) | 19 (s), 20 (n) | 24 (s), 36 (n) | 14 (s), 139 (n) |
| Socioeconomic Status subject*a | 50.8 (13.1) | 51.2 (13.6) | 50.2 (12.7) | 33.5 (12.7) |
| Socioeconomic Status caregiver*b | 33.8 (14.8) | 35.4 (14.1) | 37.6 (14.6) | 30.4 (14.7) |
| Subject Motion | ||||
| Mean Framewise Displacementc | 0.44 (0.3) | 0.42 (0.3) | 0.35 (0.2) | 0.29 (0.2) |
| Patient Population | ||||
| Duration of Illness | 18.0 (11.0) | 16.9 (12.5) | 17.0 (11.4) | n/a |
| Chlorpromazine equiv.(CPZ Woods)d | 401.1 (443.1) | 335.4 (294.6) | 367.9 (356.2) | n/a |
| Total PANSS*e | 57.7 (12.6) | 63.6 (13.5) | 54.2 (13.1) | n/a |
| PANSS-positive*e | 16.6 (4.5) | 17.8 (4.1) | 13.0 (4.1) | n/a |
| PANSS-negative | 13.7 (5.3) | 15.3 (6.1) | 13.9 (4.8) | n/a |
| Total SAPS*f | 25.1 (13.3) | 40.0 (17.4) | 12.1 (12.3) | n/a |
| Total SAPS adjusted for 2 hallucination items*g | 21.8 (12.8) | 33.9 (16.5) | 12.1 (12.3) | n/a |
*
Group ANOVA is significant at p=0.05
a
AH, VH, and NH groups all significantly different than HC (Bonferroni post-hoc, p<0.01)
b
NH vs. HC significantly different (Bonferroni post-hoc, p<0.01)
c
AH vs. HC significantly different (Bonferroni post-hoc, p<0.01); VH vs. HC significantly different (Bonferroni post-hoc, p = 0.018).
d
We only had this information for a subset of patients; percent reporting = 87.2%
e
VH vs. NH significantly different (Bonferroni post-hoc, p<0.01)
f
AH vs. NH and VH vs. NH both significantly different (Bonferroni post-hoc, p<0.01)
g
all post-hoc comparisons are significantly different (Bonferroni post-hoc, p<0.01)